Encoded Therapeutics
Encoded Therapeutics Inc. is seeking a Director of Clinical Development to provide clinical development support for multiple gene therapy programs across different stages of the drug development lifecycle. The role involves overseeing early-stage and advancing clinical programs, managing pharmacovigilance and medical monitoring, and collaborating with cross-functional teams, external experts, and regulatory agencies. The position requires strong expertise in clinical trial governance, pharmacovigilance, and medical monitoring, with a preference for experience in gene therapies, rare diseases, neurological conditions, or chronic pain management.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2014
Encoded Therapeutics is a biotechnology company focused on translating next-generation science into transformative gene therapies for neurological disorders. The company's novel targeting and regulation platform is designed to overcome first-generation gene therapy challenges by enabling greater gene specificity, cell selectivity, and potency. Encoded's lead program, ETX101, is currently in pivotal clinical development for Dravet Syndrome, with a broader precision genetic medicines neurology pipeline underway.
Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome
Dec 5, 2025
Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data
Dec 5, 2025
Phase III update Stokes hope; Dravet game-change Encoded?
Jan 12, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Encoded Therapeutics.
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
Jan 12, 2026